Comparison of the absorption of magnesium citrate and magnesium oxide in healthy subjects.

Bioavailability of organic magnesium (magnesium citrate) versus inorganic magnesium (magnesium oxide) – A single-center, randomized, 2-supplementation, 2-period, 2-sequence, single-dose, cross-over study in healthy male subjects.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12615001268538

Enrollment

Registered

2015-11-19

Start date

2015-06-19

Completion date

2015-06-26

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a randomized, controlled, cross-over study to investigate the absorption and pharmacokinetics of magnesium citrate compared with magnesium oxide after a single oral dose of magnesium. The primary outcome is the amount of magnesium excreted into the urine. The magnesium concentration in monocytes/lymphocytes and erythrocytes serve as secondary outcomes.

Interventions

20 healthy male subjects are randomized to receive an oral single-dose of magnesium citrate (equivalent to 300 mg magnesium) or magnesium oxide (equivalent to 300 mg magnesium) in a cross-over design with a 3 day wash-out period under supervision of the investigators.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

Male Caucasians aged between 18 and 45 years (including) in general good physical health and normal weight with normal renal function.

Exclusion criteria

Any illnesses or medication with influence on renal function. More than moderate alcohol consumption or history of alcohol abuse. Supplementation with magnesium. Symptoms of magnesium deficiency. Any gastrointestinal complaints.

Outcome results